Akoya Biosciences

Akoya Biosciences, based in Marlborough, Massachusetts, and listed as AKYA, makes spatial proteomics instruments, PhenoCycler and PhenoImager, used to map immune cells in tumours, and it agreed in 2025 to be acquired by Quanterix. Its multiplex immunofluorescence runs at scale, and clinical partnerships aim at spatial signatures that predict immunotherapy response. OnCo links it to spatial biology instruments. Whether a spatial immune signature can be validated as a companion diagnostic for immunotherapy, which is the promise behind the whole sector, is the open question. The spatial biology instruments page carries the wider field.